EUVIMEDEUVIMED entdecken
StudienprotokollOpen Access · CC BY 4.0

Study protocol: Fecal Microbiota Transplant combined with Atezolizumab/Bevacizumab in Patients with Hepatocellular Carcinoma who failed to achieve or maintain objective response to Atezolizumab/Bevacizumab – the FAB-HCC pilot study

Katharina Pomej iD, Adrian Frick, Bernhard Scheiner iD, Lorenz Balcar iD, Larissa Pajancic, Anton Klotz, Abelina Kreuter, Katharina Lampichler, Katharina Regnat, Kerstin Zinober, Michael Trauner, Dietmar Tamandl und 2 weitere

PLOS ONE · 15.04.2025 · 20 (4) · e0321189

DOI: 10.1371/journal.pone.0321189 ↗

Kurz gefasst

Studienprotokoll in der Zeitschrift PLOS ONE, online erschienen am 15.04.2025. Verfasst von Katharina Pomej und 13 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Bevacizumab, Carcinoma, Hepatocellular. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The gut microbiota is often altered in chronic liver diseases and hepatocellular carcinoma (HCC), and increasing evidence suggests that it may influence response to cancer immunotherapy. Strategies to modulate the gut microbiome (i.e., fecal microbiota transplant (FMT)) may help to improve efficacy of immune checkpoint inhibitors (ICIs) or even overcome resistance to ICIs. Here, we describe the design and rationale of FAB-HCC, a single-center, single-arm, phase II pilot study to assess safety, feasibility, and efficacy of FMT from patients with HCC who responded to PD-(L)1-based immunotherapy or from healthy donors to patients with HCC who failed to achieve or maintain a response to atezolizumab plus bevacizumab.

Methods

In this single-center, single-arm, phase II pilot study (ClinicalTrials.gov identifier: NCT05750030), we plan to include 12 patients with advanced HCC who failed to achieve or maintain a response to atezolizumab/bevacizumab. Patients will receive a single FMT via colonoscopy from donors with HCC who responded to PD-(L)1-based immunotherapy or from healthy individuals, followed by atezolizumab/bevacizumab every 3 weeks. The primary endpoint is safety, measured by incidence and severity of treatment-related adverse events. The main secondary endpoint is efficacy, as assessed by best radiological response according to RECISTv1.1 and mRECIST. Additional exploratory endpoints include data on the effect of FMT on recipient gut microbiota, as well as metagenomic analysis of stool samples, analyses of circulating immune cells and serum and stool proteomic, metabolomic and lipidomic signatures.

Discussion

The results of this study will help to define the potential of FMT as add-on intervention in the systemic treatment of advanced HCC, with the potential to improve efficacy of immunotherapy or even overcome resistance.

Trial registration

EudraCT Number: 2022-000234-42 Clinical trial registry & ID: ClinicalTrials.gov identifier: NCT05750030 (Registration date: 16.01.2023)

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBevacizumabCarcinoma, HepatocellularFecal Microbiota TransplantationLiver NeoplasmsAgedFemaleHumansMaleMiddle AgedGastrointestinal MicrobiomePilot ProjectsClinical Trials, Phase II as Topic

Substanzen

Antibodies, Monoclonal, HumanizedatezolizumabBevacizumab

Autor:innen und Institutionen

  • Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria.
  • Division of Gastroenterology and Hepatology, Department of Medicine III, Vienna Liver Cancer Study Group, Medical University of Vienna, Vienna, Austria.
  • Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria.

ORCID-Profile: Katharina Pomej, Bernhard Scheiner, Lorenz Balcar, Matthias Pinter

Zitieren

APA

Pomej, K., Frick, A., Scheiner, B., Balcar, L., Pajancic, L., Klotz, A., Kreuter, A., Lampichler, K., Regnat, K., Zinober, K., Trauner, M., Tamandl, D., Gasche, C., & Pinter, M. (2025). Study protocol: Fecal Microbiota Transplant combined with Atezolizumab/Bevacizumab in Patients with Hepatocellular Carcinoma who failed to achieve or maintain objective response to Atezolizumab/Bevacizumab – the FAB-HCC pilot study. PLOS ONE, 20(4), e0321189. https://doi.org/10.1371/journal.pone.0321189

Vancouver

Pomej K, Frick A, Scheiner B, Balcar L, Pajancic L, Klotz A, et al. Study protocol: Fecal Microbiota Transplant combined with Atezolizumab/Bevacizumab in Patients with Hepatocellular Carcinoma who failed to achieve or maintain objective response to Atezolizumab/Bevacizumab – the FAB-HCC pilot study. PLOS ONE. 2025;20(4):e0321189. doi:10.1371/journal.pone.0321189

BibTeX
@article{Pomej2025,
  author = {Pomej, Katharina and Frick, Adrian and Scheiner, Bernhard and Balcar, Lorenz and Pajancic, Larissa and Klotz, Anton and Kreuter, Abelina and Lampichler, Katharina and Regnat, Katharina and Zinober, Kerstin and Trauner, Michael and Tamandl, Dietmar and Gasche, Christoph and Pinter, Matthias},
  title = {Study protocol: Fecal Microbiota Transplant combined with Atezolizumab/Bevacizumab in Patients with Hepatocellular Carcinoma who failed to achieve or maintain objective response to Atezolizumab/Bevacizumab – the FAB-HCC pilot study},
  journal = {PLOS ONE},
  year = {2025},
  volume = {20},
  number = {4},
  pages = {e0321189},
  doi = {10.1371/journal.pone.0321189}
}
Kostenlos starten →